XL-184+Abiraterone in Post-Chemo CRPC

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 3, 2012

Primary Completion Date

December 31, 2014

Study Completion Date

July 1, 2021

Conditions

Prostate Cancer

Interventions

DRUG

Cabozantinib

28 day cycle

DRUG

Abiraterone

28 day cycle

Trial Locations (2)

Brigham and Women's Hospital, Boston

Dana-Farber Cancer Institute, Boston

All Listed Sponsors

lead

Dana-Farber Cancer Institute

OTHER

NCT01574937 - XL-184+Abiraterone in Post-Chemo CRPC | Biotech Hunter | Biotech Hunter